Moody Aldrich Partners LLC Sells 46 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Moody Aldrich Partners LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.5% in the third quarter, HoldingsChannel reports. The firm owned 271 shares of the biopharmaceutical company’s stock after selling 46 shares during the quarter. Moody Aldrich Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $285,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in REGN. Wealthcare Advisory Partners LLC grew its position in shares of Regeneron Pharmaceuticals by 14.4% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $283,000 after acquiring an additional 37 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of Regeneron Pharmaceuticals by 11.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 23,151 shares of the biopharmaceutical company’s stock worth $22,283,000 after purchasing an additional 2,412 shares during the last quarter. 180 Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $218,000. Fifth Third Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $217,000. Finally, Courier Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $957,000. 83.31% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on REGN. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday. Barclays reduced their price objective on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating for the company in a research note on Wednesday. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $1,260.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,101.00.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $928.90 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The company has a market capitalization of $102.40 billion, a P/E ratio of 24.60, a P/E/G ratio of 3.29 and a beta of 0.12. The company has a fifty day moving average of $1,098.29 and a 200-day moving average of $1,040.67.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period in the previous year, the firm posted $8.79 earnings per share. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.66 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.